ArticleFrontiers in allergy2025

Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis.

Daria S Fomina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.